enGene Holdings
ENGN
Market cap $220M

4.30 USD

-0.02

0.46%

At close Aug 25, 4:00 PM EDT

Pre-market

4.56

+0.26

6.05%

1 day

-0.46%

5 days

13.76%

1 month

16.22%

3 months

7.50%

6 months

-23.49%

Year to date

-39.09%

1 year

-33.64%

5 years

-78.50%

10 years

-78.50%

About: enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Employees: 57

Healthcare Biotechnology

0

Funds holding %

of 7,428 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

19% more funds holding

Funds holding: 31 [Q1] → 37 (+6) [Q2]

1.22% less ownership

Funds ownership: 80.31% [Q1] → 79.09% (-1.22%) [Q2]

20% less capital invested

Capital invested by funds: $183M [Q1] → $147M (-$36.3M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ENGN.

See Analyst Rankings

Financial journalist opinion

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducement equity awards to three newly-hired employees, with a grant date of July 31, 2025. The inducement awards consist of non-qualified stock options to purchase an aggregate 93,200 of the Company's common shares. The options each have an exercise price of $3.79 per share, which is equal to the closing p.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transition toward planned commerci.

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company's lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive,.

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in the near term. While regulatory discussions are encouraging, the investment thesis hinges on positive LEGEND trial results, making this a high-risk, high-reward scenario.

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Amy Pott, Chief Global Commercialization Officer, with a grant date of June 16, 2025. The inducement award for Ms. Pott consists of a non-qualified stock option to purchase an aggregate 400,000 of the Company's common shares. The inducement awards fo.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. “We have seen strong enrollment in the pivotal cohort of our LEGEND study,” said Ron Cooper, Chief Executive Officer of enGene. “This positions us to stay on track for our planned trial updates across all cohorts in the second.

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

enGene Announces the Resignation of its Chief Medical Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi's resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities before he departs. The Company intends to reallocate Dr. Prut.

enGene Announces the Resignation of its Chief Medical Officer

enGene to Present at the Jefferies Global Healthcare Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. A.

enGene to Present at the Jefferies Global Healthcare Conference

enGene Names Amy Pott as Chief Global Commercialization Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to.

enGene Names Amy Pott as Chief Global Commercialization Officer

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,.

enGene to Participate in Upcoming Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™